An empty response field proves nothing
FDA's warning-letter search page shows, on every row, whether a response letter and a closeout letter have been posted. A blank response-letter indicator means the firm chose not to publish one — not that none exists, and not that FDA found it wanting.
By Connor Griggs — Regulatory & Quality Strategist
FDA’s warning-letter search carries three status flags for every letter, in the same row: issued, response posted, closeout posted. Two of those sit right next to the letter as fields a reader can filter on. One of them means almost nothing when it’s blank, and the reason is not what most readers assume.
What gets posted, and who decides
A firm’s written response to a warning letter is not FDA’s to publish on its own initiative. Per FDA’s own description of the process, a response letter is posted to the search page only at the firm’s request — the recipient asks, and FDA adds the document. Nothing compels the ask, and FDA is direct that a warning letter carrying no posted response is not evidence the firm never responded, or that it isn’t working the corrective action. It is evidence of one thing only: this firm did not request publication.
A closeout letter is the opposite kind of blank
The contrast is worth naming, because the two fields sit one column apart and read like the same kind of signal. A closeout letter is FDA’s own determination, issued only once the agency has verified — usually by reinspection — that the corrective action worked; its absence can mean the firm hasn’t finished, can’t finish, or no longer exists to finish. A response letter’s absence means the firm didn’t opt into a voluntary posting. Same row, same visual weight, unrelated mechanics.
A blank cell next to a warning letter is not FDA’s report card on the firm. Read one column and it is the agency’s judgment; read the other and it is the firm’s choice not to fill it in.
What FDA Radar reads from the row
FDA Radar’s own ingestion of this source parses the posted date, the issue date, the company, the issuing office, and the subject line from each row — the fields a firm-and-device watch runs on. It does not currently read either the response-letter or the closeout-letter column; both sit in the underlying table, both are usually empty, and neither reaches a reviewer today. Noted here rather than left implied.
The practice
Treat a missing response-letter flag as uninformative, not as a data point about a firm’s posture — on a competitor’s letter or on one of your own. Per FDA Radar’s editorial standards, this is regulatory intelligence about how a public field gets populated, never regulatory advice about whether to request publication of a response.
Primary sources
Regulatory intelligence, not regulatory advice. This post describes method and published FDA records as of its date; decisions about a specific device belong with your regulatory professional.